Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

December 17, 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

News Conference News EAS 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Michael O'Riordan

October 07, 2020

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

News Daily News

Cholesterol Guidelines Fail Young MI Patients Who Might Have Benefited From Statins

August 04, 2020

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

News Daily News

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Yael L. Maxwell

April 28, 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

Pricey, Unproven ‘Executive’ CVD Screening the Norm at Top US Hospitals

News Daily News

Pricey, Unproven ‘Executive’ CVD Screening the Norm at Top US Hospitals

Michael O'Riordan

January 16, 2020

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.